The effect of botulinum toxin A in children with non-neurogenic therapy-refractory dysfunctional voiding - A systematic review.

Journal of pediatric urology 2024 Vol.20(2) p. 211-218

Hoelscher SAA, de Angst IB, Buijnsters ZA, Bramer WM, Akkermans FW, Kuindersma ME, Scheepe JR, Hoen LA'

관련 도메인

Abstract

[INTRODUCTION] Dysfunctional voiding (DV) is a habitual voiding disorder caused by involuntary contraction or non-relaxation of the external urethral sphincter (EUS) during voiding. This contraction causes high post-void residuals (PVR), urinary incontinence and urinary tract infections (UTIs). Various treatments for DV are available, but some children do not respond. Intersphincteric botulinum toxin-A (BTX-A) may be a possible treatment for therapy-refractory children with DV.

[OBJECTIVE] The aim of this systematic review is to summarize the effects and safety of intersphincteric BTX-A as a treatment for therapy-refractory DV in children.

[METHODS] A systematic search in Embase, MEDLINE, Cochrane, and Web of Science databases was performed. Studies reporting on the usage of intersphincteric BTX-A as a treatment for DV in children were included. Data on PVR, maximum flow rate (Qmax), repeat injections and complications were extracted.

[RESULTS] From a total of 277 articles, five cohort studies were identified, reporting on 78 children with DV of whom 53 were female (68 %) and 25 were male (32 %). Sample sizes ranged from ten to twenty patients. Mean or median age at the time of intervention ranged from 8 to 10.5 years. Meta-analysis could not be performed due to lack of data. The narrative synthesis approach was therefore used to summarize the results. All studies showed significant decrease in PVR after BTX-A injection. Three studies showed a 33-69 % improvement on incontinence after BTX-A injection. Less UTIs were reported after treatment. A temporary increase in incontinence, UTIs and transitory numbness to the gluteus muscle were reported as side-effects.

[CONCLUSIONS] BTX-A could be a safe and effective treatment option for therapy-refractory DV in children by reducing PVR, UTIs and incontinence. Hereby, the synergistic effect of BTX-A and urotherapy should be emphasized in future management. Furthermore, this study identified gaps in current knowledge that are of interest for future research.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 botulinum toxin 보툴리눔독소 주사 dict 2
해부 urinary tract scispacy 1
해부 urinary scispacy 1
합병증 voiding - scispacy 1
합병증 urethral sphincter scispacy 1
약물 UTIs → urinary tract infections scispacy 1
약물 BTX-A → botulinum toxin-A scispacy 1
약물 [OBJECTIVE] scispacy 1
약물 [CONCLUSIONS] BTX-A scispacy 1
약물 botulinum toxin A C0006050
botulinum toxin type A
scispacy 1
약물 [INTRODUCTION] Dysfunctional voiding scispacy 1
질환 gluteus muscle scispacy 1
질환 habitual voiding disorder scispacy 1
질환 urinary incontinence C0042024
Urinary Incontinence
scispacy 1
질환 urinary tract infections C0042029
Urinary tract infection
scispacy 1
질환 UTIs → urinary tract infections C0042029
Urinary tract infection
scispacy 1
질환 incontinence C0021167
Incontinence
scispacy 1
질환 numbness C0020580
Hypesthesia
scispacy 1
기타 botulinum toxin-A scispacy 1
기타 patients scispacy 1
기타 PVR → post-void residuals scispacy 1
기타 botulinum toxin A scispacy 1
기타 children scispacy 1

MeSH Terms

Humans; Botulinum Toxins, Type A; Child; Urination Disorders; Neuromuscular Agents; Treatment Outcome

📑 인용 관계

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문